Table 4

Characteristics of asymptomatic versus symptomatic patients (mean±SD unless otherwise stated)

ControlsAortic
stenosis
Mitral
stenosis
Aortic
regurgitation
Mitral
regurgitation
Number of subjectsNYHA 13917163216
NYHA 21714717
Total3934303933
BNP (pg/mL)NYHA 126.8±13.033.7±19.360.2±45.940.9±37.733.6±19.4
NYHA 245.0±24.886.1±50.474.2±75.952.3±29.7
p Value0.190.080.100.04
Severe valve disease, n (%)NYHA 12 (12)1 (6)19 (58)13 (81)
NYHA 26 (35)4 (29)5 (71)8 (47)
p Value0.220.160.690.04
LV end-diastolic volume index (mL/m2)NYHA 152.3±12.752.8±14.446.9±9.690.3±28.680.5±11.2
NYHA 246.6±18.139.4±11.895.7±29.572.9±15.6
p Value0.280.070.570.12
LV end-systolic volume index (mL/m2)NYHA 119.0±7.118.7±7.617.9±6.133.3±13.728.3±6.4
NYHA 222.8±15.414.9±5.436.7±16.825.6±6.5
p Value0.610.180.500.61
LV ejection fraction (%)NYHA 165±863±862±964±6.265±7
NYHA 261±663±463±765±6
p Value0.320.860.800.96
LA area index (cm2/m2)NYHA 110.6±1.911.5±2.518.2±6.010.6±2.017.4±3.9
 NYHA 211.4±2.620.5±5.911.8±2.017.6±5.0
p Value0.900.160.140.73
Pulmonary artery pressure (mm Hg)NYHA 125±430±732±1428±632±6
NYHA 235±640±831±942±16
p Value0.060.010.190.03
Valve area index/EROA index (cm2/m2)NYHA 10.51±0.090.71±0.150.11±0.070.38±0.16
NYHA 20.45±0.140.62±0.160.16±0.070.29±0.15
p Value0.150.130.060.10
Exercise capacity (METS)NYHA 112.6±3.110.9±2.87.0±3.011.3±3.611.1±1.6
NYHA 27.4±2.55.5±2.09.4±1.97.2±2.1
p Value0.0030.190.26<0.0001
  • BNP, brain natriuretic peptide; EROA, effective regurgitant orifice area; LA, left atrium; LV, left ventricle; NYHA, New York Heart Association.